Stock in Northern Virginia biotechnology company called Cel-Sci rallied as much as 21 percent Tuesday, after the company filed a patent application for an Avian flu vaccine.
The company says the application covers its drug CEL-1000 for both the prevention and treatment of bird flu.
The drug provides broad-spectrum protection, which Cel-Sci says is important against the bird flu virus because the virus exhibits a high mutation rate.
This past December, Cel-Sci signed an agreement with the National Institutes of Health to test the vaccine as a potential Avian flu vaccine in clinical trials with animals. The drug has shown positive results in other areassuch as herpes simplex virus, encephalitis and malaria.